Company Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.
The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase.
The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Country | United States |
IPO Date | Nov 15, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 58 |
CEO | Dr. Peter Blume-Jensen M.D., Ph.D. |
Contact Details
Address: 480 Arsenal Way Watertown, Massachusetts United States | |
Website | https://www.acrivon.com |
Stock Details
Ticker Symbol | ACRV |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001781174 |
CUSIP Number | 004890109 |
ISIN Number | US0048901096 |
Employer ID | 82-5125532 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer |
Dr. Eric J. Devroe Ph.D. | Chief Operating Officer |
Mary-Alice Miller J.D. | Chief Legal Officer |
Rasmus Holm-Jorgensen | Chief Financial Officer |
Bruce Close | Vice President of Quality & Compliance |
Dr. Adam D. Levy M.B.A., Ph.D. | Senior Vice President and Head of Investor Relations & Corporate Affairs |
Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer |
Katharine Peterson CPA | Vice President of Finance & Accounting |
Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer, Secretary & Director |
Parvin Miah | Vice President & Head of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 27, 2024 | 4 | Filing |
Nov 27, 2024 | 4 | Filing |
Nov 27, 2024 | 4 | Filing |
Nov 27, 2024 | 4 | Filing |
Nov 27, 2024 | 4 | Filing |
Nov 25, 2024 | 4 | Filing |
Nov 18, 2024 | 4 | Filing |
Nov 18, 2024 | 4 | Filing |
Nov 18, 2024 | 4 | Filing |
Nov 18, 2024 | 4 | Filing |